Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

22.92CHF
4:31pm BST
Change (% chg)

CHF0.34 (+1.51%)
Prev Close
CHF22.58
Open
CHF22.52
Day's High
CHF22.94
Day's Low
CHF22.52
Volume
180,287
Avg. Vol
418,950
52-wk High
CHF30.70
52-wk Low
CHF10.00

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -- -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Idorsia: US GAAP Oper Loss Of CHF 74 Mln In Q1 2018

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

19 Apr 2018

BRIEF-Idorsia FY US GAAP Loss Of CHF 8 Million

* US GAAP OPERATING RESULTS 2017: YTD LOSS OF CHF 8 MILLION; Q4 PROFIT OF CHF 71 MILLION

06 Feb 2018

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

BRIEF-Idorsia Announces Collaboration With Janssen Biotech On Aprocitentan

* IDORSIA ANNOUNCES COLLABORATION WITH JANSSEN BIOTECH ON APROCITENTAN (ACT-132577)

04 Dec 2017

Earnings vs. Estimates